Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Division of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
Expert Rev Pharmacoecon Outcomes Res. 2021 Aug;21(4):527-540. doi: 10.1080/14737167.2021.1884546. Epub 2021 Mar 11.
: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems.: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines.: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges. These include the considerable number of new oncology medicines in development including new gene therapies, new oncology medicines being launched with uncertainty regarding their value, and continued high prices coupled with the extent of confidential discounts for reimbursement. However, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments.
欧洲卫生当局越来越关注新癌症药物的价格上涨问题，这些价格不一定与健康收益挂钩，也对其医疗保健系统的可持续性产生影响。
主要是在支付方及其顾问之间就新癌症药物定价的潜在方法进行了叙述性讨论。
讨论了许多潜在的定价方法，包括新癌症药物的最低疗效水平、管理准入协议、多标准决策分析 (MCDA)、差异化/分层定价、公平定价模型、摊销模型以及脱钩模型。鉴于持续存在的挑战，我们可能会看到更多替代定价审议的增长。这些挑战包括正在开发的大量新型肿瘤学药物，包括新的基因疗法、新的肿瘤学药物在推出时其价值存在不确定性，以及持续的高价加上为报销而提供的保密折扣的程度。然而，需要平衡新癌症药物的需求。这将导致对专利肿瘤学药物价格的更严格审查，因为更多标准药物失去专利，需要更大的透明度以及包括摊销模型在内的新模型。我们将监测这些发展。
